Tesofensine/cas 195875-84-4

Tesofensine (CAS Number: 195875-84-4) is a serotonin–noradrenaline–dopamine reuptake inhibitor (SNDRI) from the phenyltropane family of drugs, primarily investigated for the treatment of obesity.
Chemical Information:
IUPAC Name: (1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
Molecular Formula: C₁₇H₂₃Cl₂NO
Molecular Weight: 328.28 g/mol
Synonym: NS 2330
Mechanism of Action: Tesofensine functions by inhibiting the reuptake of three key neurotransmitters: serotonin, noradrenaline, and dopamine. This inhibition leads to increased concentrations of these neurotransmitters in the synaptic cleft, enhancing neurotransmission and resulting in appetite suppression and potential weight loss.
Clinical Development: Initially, tesofensine was explored for treating Alzheimer's and Parkinson's diseases. However, due to limited efficacy in these areas, its development shifted focus to obesity treatment. Clinical trials have demonstrated significant weight loss in obese patients, with some studies reporting an average loss of 12.8 kg over six months at a 1 mg daily dose.